Circulating adiponectin and endometrial cancer risk

Luigino Dal Maso, Livia S A Augustin, Aspasia Karalis, Renato Talamini, Silvia Franceschi, Dimitrios Trichopoulos, Christos S. Mantzoros, Carlo La Vecchia

Research output: Contribution to journalArticle

239 Citations (Scopus)

Abstract

Circulating levels of adiponectin, a hormone with insulin-sensitizing properties, are decreased in conditions related to obesity and hyperinsulinemia, which are recognized risk factors for endometrial cancer. Eighty-seven cases with incident, histologically confirmed endometrial cancer and 132 controls admitted for acute, nonneoplastic diseases were interviewed in northeastern Italy between 1999 and 2002, and blood samples were collected. Levels of adiponectin were evaluated in samples by means of a RIA. An inverse association with endometrial cancer risk emerged for plasma adiponectin levels [odds ratio (OR), 0.42; 95% confidence interval, 0.19-0.94] when comparing the highest vs. the lowest tertiles. Similar results emerged for serum adiponectin (OR, 0.30; 95% confidence interval, 0.14-0.68). The association was stronger in pre- than in postmenopausal women, but no significant heterogeneity was observed across strata of body mass index (BMI) or parity. BMI and adiponectin showed independent effects on the risk of endometrial cancer according to a multiplicative model (OR, 6.45 in the highest level of BMI and in the lowest one of adiponectin).

Original languageEnglish
Pages (from-to)1160-1163
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number3
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Adiponectin
Endometrial Neoplasms
Body Mass Index
Odds Ratio
Confidence Intervals
Hyperinsulinism
Acute Disease
Parity
Italy
Blood
Obesity
Hormones
Insulin
Plasmas
Serum

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Dal Maso, L., Augustin, L. S. A., Karalis, A., Talamini, R., Franceschi, S., Trichopoulos, D., ... La Vecchia, C. (2004). Circulating adiponectin and endometrial cancer risk. Journal of Clinical Endocrinology and Metabolism, 89(3), 1160-1163. https://doi.org/10.1210/jc.2003-031716

Circulating adiponectin and endometrial cancer risk. / Dal Maso, Luigino; Augustin, Livia S A; Karalis, Aspasia; Talamini, Renato; Franceschi, Silvia; Trichopoulos, Dimitrios; Mantzoros, Christos S.; La Vecchia, Carlo.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 3, 03.2004, p. 1160-1163.

Research output: Contribution to journalArticle

Dal Maso, L, Augustin, LSA, Karalis, A, Talamini, R, Franceschi, S, Trichopoulos, D, Mantzoros, CS & La Vecchia, C 2004, 'Circulating adiponectin and endometrial cancer risk', Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 3, pp. 1160-1163. https://doi.org/10.1210/jc.2003-031716
Dal Maso L, Augustin LSA, Karalis A, Talamini R, Franceschi S, Trichopoulos D et al. Circulating adiponectin and endometrial cancer risk. Journal of Clinical Endocrinology and Metabolism. 2004 Mar;89(3):1160-1163. https://doi.org/10.1210/jc.2003-031716
Dal Maso, Luigino ; Augustin, Livia S A ; Karalis, Aspasia ; Talamini, Renato ; Franceschi, Silvia ; Trichopoulos, Dimitrios ; Mantzoros, Christos S. ; La Vecchia, Carlo. / Circulating adiponectin and endometrial cancer risk. In: Journal of Clinical Endocrinology and Metabolism. 2004 ; Vol. 89, No. 3. pp. 1160-1163.
@article{5b3cf93e300342598e568c776c18f90c,
title = "Circulating adiponectin and endometrial cancer risk",
abstract = "Circulating levels of adiponectin, a hormone with insulin-sensitizing properties, are decreased in conditions related to obesity and hyperinsulinemia, which are recognized risk factors for endometrial cancer. Eighty-seven cases with incident, histologically confirmed endometrial cancer and 132 controls admitted for acute, nonneoplastic diseases were interviewed in northeastern Italy between 1999 and 2002, and blood samples were collected. Levels of adiponectin were evaluated in samples by means of a RIA. An inverse association with endometrial cancer risk emerged for plasma adiponectin levels [odds ratio (OR), 0.42; 95{\%} confidence interval, 0.19-0.94] when comparing the highest vs. the lowest tertiles. Similar results emerged for serum adiponectin (OR, 0.30; 95{\%} confidence interval, 0.14-0.68). The association was stronger in pre- than in postmenopausal women, but no significant heterogeneity was observed across strata of body mass index (BMI) or parity. BMI and adiponectin showed independent effects on the risk of endometrial cancer according to a multiplicative model (OR, 6.45 in the highest level of BMI and in the lowest one of adiponectin).",
author = "{Dal Maso}, Luigino and Augustin, {Livia S A} and Aspasia Karalis and Renato Talamini and Silvia Franceschi and Dimitrios Trichopoulos and Mantzoros, {Christos S.} and {La Vecchia}, Carlo",
year = "2004",
month = "3",
doi = "10.1210/jc.2003-031716",
language = "English",
volume = "89",
pages = "1160--1163",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Circulating adiponectin and endometrial cancer risk

AU - Dal Maso, Luigino

AU - Augustin, Livia S A

AU - Karalis, Aspasia

AU - Talamini, Renato

AU - Franceschi, Silvia

AU - Trichopoulos, Dimitrios

AU - Mantzoros, Christos S.

AU - La Vecchia, Carlo

PY - 2004/3

Y1 - 2004/3

N2 - Circulating levels of adiponectin, a hormone with insulin-sensitizing properties, are decreased in conditions related to obesity and hyperinsulinemia, which are recognized risk factors for endometrial cancer. Eighty-seven cases with incident, histologically confirmed endometrial cancer and 132 controls admitted for acute, nonneoplastic diseases were interviewed in northeastern Italy between 1999 and 2002, and blood samples were collected. Levels of adiponectin were evaluated in samples by means of a RIA. An inverse association with endometrial cancer risk emerged for plasma adiponectin levels [odds ratio (OR), 0.42; 95% confidence interval, 0.19-0.94] when comparing the highest vs. the lowest tertiles. Similar results emerged for serum adiponectin (OR, 0.30; 95% confidence interval, 0.14-0.68). The association was stronger in pre- than in postmenopausal women, but no significant heterogeneity was observed across strata of body mass index (BMI) or parity. BMI and adiponectin showed independent effects on the risk of endometrial cancer according to a multiplicative model (OR, 6.45 in the highest level of BMI and in the lowest one of adiponectin).

AB - Circulating levels of adiponectin, a hormone with insulin-sensitizing properties, are decreased in conditions related to obesity and hyperinsulinemia, which are recognized risk factors for endometrial cancer. Eighty-seven cases with incident, histologically confirmed endometrial cancer and 132 controls admitted for acute, nonneoplastic diseases were interviewed in northeastern Italy between 1999 and 2002, and blood samples were collected. Levels of adiponectin were evaluated in samples by means of a RIA. An inverse association with endometrial cancer risk emerged for plasma adiponectin levels [odds ratio (OR), 0.42; 95% confidence interval, 0.19-0.94] when comparing the highest vs. the lowest tertiles. Similar results emerged for serum adiponectin (OR, 0.30; 95% confidence interval, 0.14-0.68). The association was stronger in pre- than in postmenopausal women, but no significant heterogeneity was observed across strata of body mass index (BMI) or parity. BMI and adiponectin showed independent effects on the risk of endometrial cancer according to a multiplicative model (OR, 6.45 in the highest level of BMI and in the lowest one of adiponectin).

UR - http://www.scopus.com/inward/record.url?scp=1642415981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642415981&partnerID=8YFLogxK

U2 - 10.1210/jc.2003-031716

DO - 10.1210/jc.2003-031716

M3 - Article

C2 - 15001602

AN - SCOPUS:1642415981

VL - 89

SP - 1160

EP - 1163

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -